Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2018 2
2019 4
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial.
Maruyama T, Maruyama N, Higuchi T, Nagura C, Takashima H, Kitai M, Utsunomiya K, Tei R, Furukawa T, Yamazaki T, Okawa E, Ando H, Kikuchi F, Abe M. Maruyama T, et al. Among authors: tei r. Eur J Clin Nutr. 2019 Feb;73(2):293-301. doi: 10.1038/s41430-018-0348-y. Epub 2018 Oct 23. Eur J Clin Nutr. 2019. PMID: 30353121 Clinical Trial.
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
Takashima H, Yoshida Y, Nagura C, Furukawa T, Tei R, Maruyama T, Maruyama N, Abe M. Takashima H, et al. Among authors: tei r. Diab Vasc Dis Res. 2018 Sep;15(5):469-472. doi: 10.1177/1479164118782872. Epub 2018 Jun 20. Diab Vasc Dis Res. 2018. PMID: 29923427 Free article. Clinical Trial.
Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage.
Furukawa T, Okada K, Abe M, Tei R, Oikawa O, Maruyama N, Maruyama T. Furukawa T, et al. Among authors: tei r. Int J Mol Sci. 2015 Dec 18;16(12):30181-9. doi: 10.3390/ijms161226229. Int J Mol Sci. 2015. PMID: 26694377 Free PMC article. Clinical Trial.
Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Abe M, Higuchi T, Moriuchi M, Okamura M, Tei R, Nagura C, Takashima H, Kikuchi F, Tomita H, Okada K. Abe M, et al. Among authors: tei r. Diabetes Res Clin Pract. 2016 Jun;116:244-52. doi: 10.1016/j.diabres.2016.04.034. Epub 2016 Apr 26. Diabetes Res Clin Pract. 2016. PMID: 27321342 Free article. Clinical Trial.